JPMorgan Chase & Co. Reiterates Overweight Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “overweight” rating reissued by JPMorgan Chase & Co. in a research report issued on Thursday, MarketBeat.com reports. They currently have a £140 price objective on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 3.00% from the stock’s current price.

AZN has been the topic of a number of other research reports. Berenberg Bank boosted their price target on AstraZeneca from £142 to £145 and gave the company a “buy” rating in a report on Tuesday, October 21st. Jefferies Financial Group reiterated a “buy” rating and issued a £150 price target on shares of AstraZeneca in a report on Monday, November 10th. Finally, Shore Capital reissued a “buy” rating and set a £145 price objective on shares of AstraZeneca in a research report on Thursday, November 6th. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of £138.

AstraZeneca Stock Up 0.6%

Shares of AZN opened at £135.92 on Thursday. AstraZeneca has a 1 year low of GBX 9,573.51 and a 1 year high of £142.06. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. The stock has a 50 day simple moving average of £129.82 and a two-hundred day simple moving average of £116.89. The firm has a market cap of £210.71 billion, a P/E ratio of 25.60, a P/E/G ratio of 0.86 and a beta of 0.17.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.